BridgeMD
New treatment option for Central Venous Catheter
Official title Contact Activation of Coagulation in Newly Inserted Central Venous Catheters
ClinicalTrials.gov ID: NCT07014722
What this study is testing
- What it's testing
- A central venous catheter (CVC) is a thin plastic tube placed into one of the body's large veins, typically in the neck or near the clavicle. CVCs are crucial for administering medications, fluids, and secure blood samples.
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Participants must meet all of the following criteria to be included in the study:
- Clinical indication for the placement of a two-lumen central venous catheter with length 150-160 mm.
- Age ≥18 years.
- Signed informed consent.
You likely can't join if
- Participants meeting any of the following criteria will be excluded:
- Current use of anticoagulants or platelet inhibitors, except: Prophylactic low molecular weight heparin (LMWH), double prophylactic dose of LMWH...
- Prothrombin complex (pK/INR) outside the normal range (0.9-1.2), platelet count \<50 × 10⁹/L or haemoglobin \< 80 g/L, if already available.
- Known coagulopathic conditions, including but not limited to:
- Activated protein C (APC) resistance,
- Hemophilia A or B,
See the full eligibility criteria
- Participants must meet all of the following criteria to be included in the study:
- Clinical indication for the placement of a two-lumen central venous catheter with length 150-160 mm.
- Age ≥18 years.
- Signed informed consent.
- Participants meeting any of the following criteria will be excluded:
- Current use of anticoagulants or platelet inhibitors, except: Prophylactic low molecular weight heparin (LMWH), double prophylactic dose of LMWH, Acetylsalicylic acid (ASA).
- Prothrombin complex (pK/INR) outside the normal range (0.9-1.2), platelet count \<50 × 10⁹/L or haemoglobin \< 80 g/L, if already available.
- Known coagulopathic conditions, including but not limited to:
- Activated protein C (APC) resistance,
- Hemophilia A or B,
- Vitamin K deficiency,
- Disseminated intravascular coagulation (DIC),
- Antiphospholipid syndrome,
- von Willebrand disease, Other known congenital or acquired bleeding disorders.
The study team makes the final eligibility decision.
Where it's taking place
- Lund, Skåne County, Sweden
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Lund, Skåne County, Sweden. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.